Valneva SE

Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

16 9月 2022 16:30:00 条件 Nasdaq GlobeNewswire

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

08 9月 2022 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

06 9月 2022 01:00:00 条件 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: August 31, 2022

05 9月 2022 12:00:00 条件 Nasdaq GlobeNewswire

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

29 8月 2022 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

23 8月 2022 11:45:00 条件 Nasdaq GlobeNewswire

Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

18 8月 2022 12:00:00 条件 Nasdaq GlobeNewswire

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

18 8月 2022 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

15 8月 2022 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Reports H1 2022 Results and Provides Corporate Updates

11 8月 2022 01:00:00 条件 Nasdaq GlobeNewswire